Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04112498
Title A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb

urinary bladder cancer

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma


gastric adenocarcinoma

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma


Nivolumab + Relatlimab + rHuPH20

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.